The company has a very strong cash position, but has recently doubled its authorized shares and maintains significant convertible debt and a new ATM program. These actions create a high risk of significant future dilution for shareholders.
Float & OS: 510,748,848 / 512,943,561
Est. Runway: ~26 months
Risk Metrics
Overall Risk
HIGH
Offering Ability
SEVERE
Cash Need
LOW
Float Risk
HIGH
Dilution Data
Warrants
No warrants that would dilute common stock were identified in the filings. The company holds warrants in another entity as an investment asset.
Convertible Notes
Senior Secured Exchangeable Notes due 2030: An indenture amendment has altered the "Exchange Rate" definition to "$1,000 divided by 87.5% of the Unadjusted Exchange Price," which is subject to further adjustments. This change affects the number of shares issued upon exchange.
6.00%/8.00% Cash/PIK Toggle Exchangeable Notes: Approximately $107.3 million in principal remains outstanding.
New Exchangeable Notes: Approximately $154.5 million in principal remains outstanding and became exchangeable following shareholder approval for the authorized share increase.
The total number of shares to be issued upon conversion for all notes is now subject to the amended, more dilutive exchange rate.
ATMs
The company previously sold all 50.0 million shares authorized under a prior agreement, raising $63.0 million in gross proceeds from the sale of 17.1 million shares during the nine months ended September 30, 2025.
A new "at-the-market" (ATM) offering program is planned, allowing for the sale of common stock for aggregate net proceeds up to $150,000,000. This program cannot commence before February 2, 2026.
Additional Notes
Authorized Share Increase: Stockholders approved an increase in authorized Class A common stock from 550,000,000 to 1,100,000,000 shares on December 10, 2025, significantly expanding the company's ability to issue new equity.
Stock-Based Compensation: As of September 30, 2025, there were 6,761,780 nonvested RSUs and PSUs outstanding. An additional 3,000,921 PSUs were awarded for future years, representing further potential dilution.
Consent Fee: A $6,250,000 consent fee related to the convertible note indenture amendments will be paid in shares of common stock. The number of shares will be determined by a 60-day VWAP starting December 22, 2025.
Forward Sales: A forward sale of 30,000,000 shares was completed, with the valuation period ending in March 2025. This represents a past dilutive event.